These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21639814)

  • 1. Expert opinion on current therapies for nonalcoholic fatty liver disease.
    Della Corte C; Alisi A; Iorio R; Alterio A; Nobili V
    Expert Opin Pharmacother; 2011 Aug; 12(12):1901-11. PubMed ID: 21639814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease: pharmacologic and surgical options.
    Parikh N; Ahmad J
    Gastroenterol Clin North Am; 2011 Sep; 40(3):541-59. PubMed ID: 21893273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease.
    Paredes AH; Torres DM; Harrison SA
    Clin Liver Dis; 2012 May; 16(2):397-419. PubMed ID: 22541706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver in children and adolescents: an overview.
    Della Corte C; Alisi A; Saccari A; De Vito R; Vania A; Nobili V
    J Adolesc Health; 2012 Oct; 51(4):305-12. PubMed ID: 22999829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome.
    Moscatiello S; Di Luzio R; Sasdelli AS; Marchesini G
    Expert Opin Pharmacother; 2011 Dec; 12(17):2657-72. PubMed ID: 22043839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for non-alcoholic steatohepatitis.
    Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.
    Marchesini G; Moscatiello S; Agostini F; Villanova N; Festi D
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):121-36. PubMed ID: 21352073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeuric aspects of NAFLD. A literature review].
    Tapia NC; Avila FI; Leiva JG; Ramos MH; Avila JF; Uribe M
    Rev Gastroenterol Mex; 2006; 71(4):487-95. PubMed ID: 17542283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS; Oben J
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR; Torres DM; Harrison SA
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments.
    Alisi A; Nobili V
    Nutrition; 2012 Jul; 28(7-8):722-6. PubMed ID: 22464551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies in nonalcoholic fatty liver disorders.
    Poordad FF
    Expert Opin Emerg Drugs; 2005 May; 10(2):237-9. PubMed ID: 15934865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The trials and tribulations of the treatment of nonalcoholic fatty-liver disease.
    Gan SK; Adams LA; Watts GF
    Curr Opin Lipidol; 2008 Dec; 19(6):592-9. PubMed ID: 18957882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
    Barshop NJ; Sirlin CB; Schwimmer JB; Lavine JE
    Aliment Pharmacol Ther; 2008 Jul; 28(1):13-24. PubMed ID: 18397387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease: current and potential therapies.
    Ibrahim MA; Kelleni M; Geddawy A
    Life Sci; 2013 Feb; 92(2):114-8. PubMed ID: 23159641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease in the pediatric population.
    Lavine JE; Schwimmer JB
    Clin Liver Dis; 2004 Aug; 8(3):549-58, viii-ix. PubMed ID: 15331063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.